Last update 17 May 2026

Hangzhou Bangshun Pharmaceutical Co Ltd

Private Company | Subsidiary Company|2020|Zhejiang Sheng, China|
biosunpharma.com

Overview

Tags

Other Diseases
Immune System Diseases
Neoplasms
Small molecule drug
Degradable Molecular Glue

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms9
Immune System Diseases6
Nervous System Diseases4
Hemic and Lymphatic Diseases3
Endocrinology and Metabolic Disease3
Infectious Diseases2
Top 5 Drug TypeCount
Small molecule drug9
Degradable Molecular Glue2
Unknown1
Top 5 TargetCount
KEAP1 x Nrf21
KEAP1(Kelch-like ECH-associated protein 1)1
JAK2(Tyrosine-protein kinase JAK2)1
BTK(Tyrosine-protein kinase BTK)1
METTL3(methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit)1

Related

12
Drugs associated with Hangzhou Bangshun Pharmaceutical Co Ltd
Bewintinib
Target
JAK2
Mechanism
JAK2 inhibitors
Active Org.
Hangzhou Bangshun Pharmaceutical Co Ltd [+1]
Originator Org.
Hangzhou Guangliang Biomedical Co., Ltd.
Active Indication
Post-essential thrombocythemia myelofibrosis [+8]
Inactive Indication
Dermatitis, Atopic [+1]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
China
First Approval Date29 Apr 2026
CX1440
Target
BTK
Mechanism
BTK inhibitors
Active Org.
Hangzhou Bangshun Pharmaceutical Co Ltd [+2]
Originator Org.
Hangzhou Sanyintai Pharmaceutical Technology Co Ltd
Active Indication
Purpura, Thrombocytopenic, Idiopathic [+6]
Inactive Indication
Multiple Sclerosis, Chronic Progressive [+1]
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
CX16
Target
VAV1
Mechanism
VAV1 degraders
Active Org.
Hangzhou Bangshun Pharmaceutical Co Ltd
Originator Org.
Hangzhou Bangshun Pharmaceutical Co Ltd
Active Indication
Inflammatory Bowel Diseases [+2]
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
14
Clinical Trials associated with Hangzhou Bangshun Pharmaceutical Co Ltd
CTR20254581
/ CompletedPhase 1
贝泽昔替尼（OB756）片在健康参与者中随机、开放、两制剂、两周期、双交叉的药代动力学研究
[Translation] A randomized, open-label, two-formulation, two-period, dual-crossover pharmacokinetic study of bezacitinib (OB756) tablets in healthy participants.
CTR20253385
/ RecruitingPhase 3
评价邦赛替尼胶囊对照安慰剂治疗慢性原发免疫性血小板减少症(ITP)成人患者中的有效性和安全性的随机、双盲对照、多中心Ⅲ期临床研究
[Translation] A randomized, double-blind, multicenter phase III clinical study to evaluate the efficacy and safety of bonsetinib capsules versus placebo in the treatment of adult patients with chronic immune thrombocytopenia (ITP)
CTR20253179
/ RecruitingPhase 1/2
评估邦赛替尼（CX1440）胶囊在成人慢性荨麻疹患者中的有效性、安全性和药物相互作用的Ⅰ/Ⅱ期临床研究
[Translation] A Phase I/II clinical study to evaluate the efficacy, safety, and drug interactions of bonsetinib (CX1440) capsules in adult patients with chronic urticaria
100 Clinical Results associated with Hangzhou Bangshun Pharmaceutical Co Ltd
Login to view more data
0 Patents (Medical) associated with Hangzhou Bangshun Pharmaceutical Co Ltd
Login to view more data
100 Deals associated with Hangzhou Bangshun Pharmaceutical Co Ltd
Login to view more data
100 Translational Medicine associated with Hangzhou Bangshun Pharmaceutical Co Ltd
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 May 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
5
5
Preclinical
IND Approval
1
1
Phase 3
Approved
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Bewintinib
 ( JAK2 )		Acute Graft Versus Host Disease
More
Phase 1/2
CX1440
 ( BTK )		Autoimmune Haemolytic Anaemias
More
IND Approval
CX510
 ( HER2 )		Solid tumor
More
IND Approval
CX16
 ( VAV1 )		Inflammatory Bowel Diseases
More
Preclinical
CX13
 ( PPARγ )		Solid tumor
More
Preclinical
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free